Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)

Inclusion Criteria: .

* Histologically proven advanced solid tumors that are considered appropriate for treatment in Period 2 of this study, for which no effective standard therapy exists, or standard therapy has failed or cannot be tolerated
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) =\< 1
* Evaluable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) at Screening
* Participant has adequate renal, hematological and hepatic function
* Other protocol defined inclusion criteria could apply

Exclusion Criteria:

* Participants with uncontrolled intercurrent illness including, but not limited to, severe active infection including, acute respiratory syndrome coronavirus-2 infection/coronavirus disease 2019 (Covid 19), immune deficiencies, uncontrolled diabetes, uncontrolled arterial hypertension and symptomatic congestive heart failure
* Concurrent participation in another interventional clinical study is not permitted.
* Known hypersensitivity to the study interventions, a similar structural compound, or to one or more excipients used
* Prior or concurrent treatment with a nonpermitted drug/intervention from the first dose of study intervention administration, as defined per protocol.
* Other protocol defined exclusion criteria could apply